Copyright
©2013 Baishideng Publishing Group Co.
World J Transl Med. Dec 12, 2013; 2(3): 32-35
Published online Dec 12, 2013. doi: 10.5528/wjtm.v2.i3.32
Published online Dec 12, 2013. doi: 10.5528/wjtm.v2.i3.32
Figure 1 Structure of the proteasome inhibitor bortezomib.
The amino acid residue marked in red at the C-terminus (boroLeu unit) is responsible for its β5-preferring (chymotrypsin-like) activity and represents the electrophilic moiety that covalently traps the catalytic Thr1Oγ with a slow off-rate.
- Citation: Micale N. Peptide-based boronates: How to achieve tissue specificity in anticancer therapy. World J Transl Med 2013; 2(3): 32-35
- URL: https://www.wjgnet.com/2220-6132/full/v2/i3/32.htm
- DOI: https://dx.doi.org/10.5528/wjtm.v2.i3.32